Chemomab Therapeutics (NASDAQ:CMMB) Downgraded to Hold Rating by Zacks Research

Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

CMMB has been the subject of a number of other research reports. Oppenheimer boosted their target price on Chemomab Therapeutics from $10.00 to $25.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $26.50.

Chemomab Therapeutics Stock Down 1.1%

NASDAQ CMMB opened at $2.70 on Tuesday. Chemomab Therapeutics has a fifty-two week low of $2.39 and a fifty-two week high of $9.84. The business has a fifty day moving average of $2.90 and a 200-day moving average of $3.92. The stock has a market cap of $13.97 million, a price-to-earnings ratio of -0.91 and a beta of 0.64.

Institutional Investors Weigh In On Chemomab Therapeutics

An institutional investor recently raised its position in Chemomab Therapeutics stock. Virtu Financial LLC lifted its stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,803 shares of the company’s stock after purchasing an additional 16,358 shares during the period. Virtu Financial LLC owned about 0.21% of Chemomab Therapeutics worth $34,000 as of its most recent filing with the SEC. 46.05% of the stock is currently owned by institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).